1 INTRODUCTION {#SEC1}
==============

Next Generation Sequencing machines, e.g. Illumina Genome Analyzer (Illumina Inc., San Diego, CA, USA) and SOLiD (Applied Biosystems, Foster City, CA, USA), are capable of producing millions of relatively short (20--55 bases) genomic subsequences (*reads*) in one (2--3 days) run (Illumina, [@B4], [@B5], [@B6]). Efficient and less expensive than traditional Sanger sequencing, the Illumina Genome Analyzer (G1) has drawn many authors in sequencing (and analyzing) hundreds of genomic samples (Illumina, [@B6]; Kathryn *et al*., [@B8]; Srivatsan *et al*., [@B11]). Due to the large amount of data produced, the final user of the data may find difficult accomplishing important tasks such as estimating how much useful data were produced, detecting defective *tiles*/*lanes* present on the *flow cell*, or identifying the maximum length of *reads* which can be used without compromising base calls quality. The study of quality issues of the data produced is an active area of research for next generation sequencing with efforts elsewhere (Dolan and Denver, [@B3]) that could be complementary to the work presented here.

Early detection of various problems that can appear during the sample preparation and sequencing process significantly reduce time and effort required for more sophisticated steps of analysis, such as *de novo* sequence assembly or mapping *reads* to reference sequences. Herein, we present a simple quality analysis pipeline (PIQA), developed to be used on regular desktop PCs or as an 'extension' of the standard Illumina Genome Analyzer software (Illumina pipeline). PIQA reads data in the *bustard*, *fastq* and *scarf* formats and eases the visual identification of technical problems, including mistakes in sample/library preparations, defective *tiles*/*lanes* and abnormalities in the frequencies of appearance of genomic *reads*.

2 FEATURES {#SEC2}
==========

2.1 Structure of the data {#SEC2.1}
-------------------------

Each sequencing run of an Illumina Genome Analyzer G1 uses a single glass *flow cell* consisting of eight independent *lanes* (each *lane* may contain a different DNA sample). Each *lane* is populated with randomly fragmented genomic DNA previously capped at both ends with two types of DNA subsequences (*adapters*). One type of *adapters* allows the sequence to be attached to the surface of the *flow cell* and it is also used during the amplification phase to form *clusters* of the same type of sequence on the surface. A second type of *adapters* attach to the opposite end of the sequences acting as primers from which the sequencing-by-synthesis starts (Bentley, [@B1]; Church, [@B2]; Illumina, [@B4], [@B7]). The sequencing phase may consist of 20--50 *cycles* (Illumina, [@B5]), limited by the probability (or the corresponding *quality score*) with which each nucleotide can be identified. The quality score decreases as the number of *cycles* increases. The standard Illumina quality score is represented by an integer value that ranges from −40 to +40; an average score above +10 is considered acceptable. The total number of sequencing *cycles* corresponds to the length of sequences produced (*reads*). During each cycle, every *lane* is imaged four times using a different wavelength for each nucleotide. These images are collected as the camera sweeps up and down each *lane* three times, covering 100--110 (depending on the Illumina software release used) non-overlapping *tiles* on each sweep. Once the sequencing process is finished, the image files go into the image analysis stage of the Illumina pipeline (called *FIRECREST*). The pipeline continues to a base-calling stage (called *BUSTARD*) that assigns quality scores and determines the cluster\'s sequence. The final stage of the pipeline (*GERALD*) filters out low-quality *reads* and trims the sequences by excluding low-quality prefixes and/or suffixes of all the *reads*, while still keeping the length of all the *reads* equal.

In a successful run, the average number of *reads* produced for a single *lane* varies from 2 to 10 million for unfiltered data (1--6 million for filtered data). The size of the text files containing 5 M *reads* of 36 nt. varies from ≈245 Mb (*bustard* format) if only sequencing *reads* are included, to ≈725 Mb in *fastq* format, if the quality of each nucleotide is included.

Various problems which may occur in each step of the sample preparation and sequencing can be detected by an analysis of the variation of clusters density; base-call proportions; and base quality across *cycles* of the run, and across *tiles* and *lanes* of the *flow cell*.

PIQA processes data of one *flow cell lane* at a time and outputs three HTML documents. The main page of the report (PIQA_report.html) consists of a sequencing summary showing general information about the run, a set of graphs and links to two complementary HTML pages. The graphs displayed in PIQA_report.html assess the clusters density per *tile*, the base-calls proportions per *tile* and per *cycle*, and finally the base-calls quality per *tile* and per *cycle*. The complementary HTML documents show the proportion of base-calls per *tile* for each *cycle* and the average quality of base-calls per *tile* for each *cycle*.

2.2 Density of clusters {#SEC2.2}
-----------------------

The total number of clusters (*reads*) across the *lane* can serve as an indicator of the overall success of a sequencing run ([Fig. 1](#F1){ref-type="fig"}a). Various mechanical, optical and sample preparation issues can, however, significantly disturb the expected pattern. Frequently observed abnormalities include: poor sample quality and/or poor accuracy in DNA quantitation, leading to cluster densities either too high or too low across the entire *lane*; problems with the optical system, causing decreased cluster density (usually for all the *lanes* on the *flow cell*); and finally, mechanical defects such as oil drops and cracks causing decrease in the density of clusters across neighboring *tiles*. Fig. 1.Example output of the PIQA program.

2.3 Base calls {#SEC2.3}
--------------

Ideally, since each *lane* is populated by randomly fragmented genomic DNA, the proportion of nucleotides (denoted by A, T, C, G and N---for unknown base calls) observed in each *tile*, *lane* and *cycle* is expected to be identical. Deviation from this pattern could be a signature of major technical and/or sample preparation problems, for instance, optical failures or sequence bias introduced during the sample preparation. In [Figure 1](#F1){ref-type="fig"}b, too many *adapter* sequences were introduced during sample preparation, causing the sequencing of *adapters* instead of the sample. In [Figure 1](#F1){ref-type="fig"}c, the first 20 nt were affected by the primer used during whole genome amplification.

PIQA produces a simple but useful quality analysis of the data. For example, considering quality scores below + 10 as unacceptable, *tile*-by-*tile* ([Fig. 1](#F1){ref-type="fig"}d) and *cycle*-by-*cycle* ([Fig. 1](#F1){ref-type="fig"}e) plots of the average quality score for each base allows one to make an educated decision about which *tiles* need to be excluded from consideration and if the trimming of *reads* (exclusion of prefix and/or suffix parts of *reads*) is required.

3 IMPLEMENTATION {#SEC3}
================

The PIQA package is implemented in R (R Development Core Team, [@B10]) and C++. Versions for Windows-32; LINUX-32 and 64; and Mac OS X-32 and 64, are available for download on the Supplementary web site. PIQA makes use of the R2HTML (Lecoutre, [@B9]) library, and it is implemented as a pipeline in two stages: the first part generates a text summary file (also available to the user for further analyses), the second part uses this summary to produce an HTML report.

PIQA was developed in collaboration between the Bioinformatics Laboratory of the University of Houston and Eureka Genomics Corp.
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